Cargando…

Lutetium DOTATATE whole body scans: A novel approach for evaluation of neuroendocrine tumors

AIM: We undertook a study to evaluate whether Lutetium (Lu) DOTATATE whole body scan is well comparable to Gallium positron emission tomography (PET) / Indium Octreotide, and hence with dosimetric advantage can replace it in the pre-therapy setting. MATERIALS AND METHODS: We undertook a prospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Natasha, Krishna, BA, Vyas, Madhusudan, Venkatesh, Meera, Banerjee, Sharmila, Das, Tapas, Nair, KV Vimal, Sudipta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543578/ https://www.ncbi.nlm.nih.gov/pubmed/23326064 http://dx.doi.org/10.4103/0972-3919.103994

Ejemplares similares

(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

SHDB mutant functional metastatic paraganglioma: The efficacy of Lutetium-177 DOTATE
por: Erturk, Banu, et al.
Publicado: (2023)

Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
por: Smith-Palmer, J., et al.
Publicado: (2021)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
por: Zhang, Vivian, et al.
Publicado: (2023)

Initial clinical evaluation of indigenous (90)Y-DOTATATE in sequential duo-PRRT approach ((177)Lu-DOTATATE and (90)Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, (90)Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects
por: Parghane, Rahul V., et al.
Publicado: (2020)

Lutetium-labelled peptides for therapy of neuroendocrine tumours
por: Kam, B. L. R., et al.
Publicado: (2012)

Software-assisted dosimetry in peptide receptor radionuclide therapy with (177)Lutetium-DOTATATE for various imaging scenarios
por: Kupitz, Dennis, et al.
Publicado: (2017)

MON-214 Biochemical Abnormalities in Endocrine Function Associated with Lutetium 177-DOTATATE Therapy in Metastatic Pheochromocytoma and Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2020)

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor
por: Shell, Jasmine, et al.
Publicado: (2018)

(68)Ga-DOTATATE Radioisotope scan to detect neuroendocrine tumors; A Cross-Sectional Study
por: Doroudinia, Abtin, et al.
Publicado: (2022)

Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Image Findings of a Rare Case of Neuroendocrine Tumor Metastatic to Orbital Extraocular Muscle in Gallium-68 DOTANOC Positron Emission Tomography/Computed Tomography and Therapy with Lutetium-177 DOTATATE
por: Kamaleshwaran, Koramadai Karuppusamy, et al.
Publicado: (2017)

Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium—177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience
por: de Souza, Zenaide Silva, et al.
Publicado: (2023)

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
por: Vida Navas, Elena María, et al.
Publicado: (2021)

(68)Ga-DOTATATE positron emission tomography/computed tomography scan in the detection of bone metastases in pediatric neuroendocrine tumors
por: Goel, Reema, et al.
Publicado: (2014)

Lutetium ultraphosphate
por: Horchani-Naifer, Karima, et al.
Publicado: (2008)

SAT-502 Clinical Hypothyroidism Associated with Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma: A Novel Adverse Effect of Peptide Receptor Radionuclide Therapy
por: Gubbi, Sriram, et al.
Publicado: (2020)

Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms
por: Saracyn, Marek, et al.
Publicado: (2022)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

Testicular Metastasis of Jejunal Neuroendocrine Tumor on (68)Ga-DOTATATE PET/CT
por: Şahin, Ömer Faruk, et al.
Publicado: (2023)

Imaging and treatment with (68)Gallium and (177)Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung
por: Kumaran, Arjunan, et al.
Publicado: (2022)

Cost-effectiveness of lutetium ((177)Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden
por: Palmer, Jayne, et al.
Publicado: (2020)

Nuclear deformation of lutetium isotopes
por: Ekström, C
Publicado: (1974)

Ileal Neuroendocrin Tumor Metastasis to Breast Diagnosed with Ga-68 DOTATATE PET/CT
por: Sağlampınar Karyağar, Sevda, et al.
Publicado: (2019)

Evaluation of (177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
por: Abou Jokh Casas, Estephany, et al.
Publicado: (2020)

Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?
por: Kunikowska, Jolanta, et al.
Publicado: (2011)

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of (177)Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
por: Sundquist, Fredrik, et al.
Publicado: (2022)

Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study
por: Bober, Barbara, et al.
Publicado: (2022)

The therapeutic efficacy of (177)Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis
por: Wang, Li-fan, et al.
Publicado: (2020)

Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients
por: Pettersson, Olof, et al.
Publicado: (2020)

The HSP90 inhibitor onalespib potentiates (177)Lu-DOTATATE therapy in neuroendocrine tumor cells
por: Lundsten, Sara, et al.
Publicado: (2019)

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with (177)Lu-DOTATATE
por: Pettersson, Olof Joakim, et al.
Publicado: (2021)

Widespread micronodular hepatic metastases of neuroendocrine tumor detected by [(68)Ga]DOTATATE PET/CT
por: D'Souza, Julia C., et al.
Publicado: (2022)

The Influence of Long-Acting Somatostatin Analogs on (68)Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors
por: Chahid, Youssef, et al.
Publicado: (2023)

Lutetium(III) cyclotetraphosphate
por: Mbarek, Aïcha, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2u9mrt57h8t1kjiba6qhtgdl2d